Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$47.61 USD
-0.19 (-0.40%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $47.60 -0.01 (-0.02%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Agios Pharmaceuticals, Inc. [AGIO]
Reports for Purchase
Showing records 101 - 120 ( 303 total )
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Announces Pyrukynd?s Annual Price to Treat Patients with PKD; Reiterate Buy and $98 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Fully Rebooted Post-FDA Pyrukynd Approval in PKD; Reiterate Buy and Raise PT to $98 from $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 21.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 14.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Previews Milestones and Strategy for 2022; Reiterate Buy and $95 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended December 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended December 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended December 10
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Two Studies at ASH Corroborate Previous Findings for Mitapivat; Reiterate Buy and $95 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended November 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended October 29.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Largely Pro Forma 3Q21 Belies Great Things to Come for Agios; Reiterate Buy and Slight PT Raise to $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended October 22.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department